MVM Life Science Partners — Full Portfolio
10 tracked investments · listed companies and verified rows first
AccuVein makes near-infrared (NIR) vein visualization devices that let clinicians see veins, valves, and bifurcations beneath the skin to guide peripheral IV insertion and vascular access.
HardwareHealthtechMedical DevicesCold Spring Harbor, US
Ron Goldman(Executive Officer, Director)
BoardJames Lackie(Director)Eric Bednarski(Director)Frank Flaut III(Director)Christopher Gabrieli(Director)
Board seatStephen ReedersAkhilesh Pathipati· per SEC Form D · $18.3M raise · filed Apr 2022
CurvaFix develops the CurvaFix Low Profile intramedullary nailing system, curved implants for surgical stabilization of pelvic fractures.
HardwareHealthtechMedical DevicesBellevue, US
Jeffrey Poole(Executive Officer)Mark Foster(Executive Officer, Director)Steven Dimmer(Executive Officer, Director, Promoter)Dong-Gun Kim(Director)
Board seatJack TanakaEric Fritz· per SEC Form D
Co-investorsAlliance of AngelsRockies Venture ClubSPRINGROCK VENTURESSwan Venture FundKeiretsu CapitalSectoral Asset Management+1 more
BiotechNewport Beach, US
Davis Corley(Executive Officer)J. Andy Corley(Executive Officer, Director, Promoter)
Board seatEric BednarskiAkhilesh Pathipati· per SEC Form D · $67.6M raise · filed Sep 2022
Co-investorsVersant Venture AIV Holdings
Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists.
BiotechHealthtechMedical DevicesYardley, US
Per Djupesland(Executive Officer, Director)Michele Janis(Executive Officer)Peter Miller(Executive Officer, Director)Terrence Terifay(Executive Officer)Ramy Mahmoud(Executive Officer)
BoardKlaas De Boer(Director)
Board seatEric BednarskiKyle Dempsey· per SEC Form D · $4.7M raise · filed May 2024
Co-investorsForesite Capital
Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.
BiotechPhiladelphia, US
David Brand(Executive Officer, Director)Gregory Lumpkin(Executive Officer)
BoardRichard Kollender(Director)Martin Edwards(Director)Derek Ferguson(Director)
Board seatEric Bednarski· per SEC Form D · $2M raise · filed Feb 2016
Co-investorsForesite Capital
HealthtechCampbell, US
Nersi Nazari(Executive Officer, Director)Steve Zadig(Executive Officer, Director)
BoardRichard Feachem(Director)Tom Saunders(Director)
Board seatStephen Reeders· per SEC Form D · $38.1M raise · filed Oct 2017
Co-investorsAsahi Kasei Corporate Venture CapitalEssex Woodlands Healthcare PartnersRevelation Partners
Campbell, US
Amir Belson(Director)John Tighe(Executive Officer, Director)
BoardPatrick Berbon(Director)Balaji Muralidhar(Director)
Board seatStephen Reeders· per SEC Form D · $26.9M raise · filed Jan 2016
GammaTile Therapy, a surgically targeted radiation therapy for operable brain tumors
HealthtechTempe, US
David G. Brachman(Executive Officer, Director)Per Langoe(Executive Officer, Director)James Leech(Executive Officer)Matthew E. Likens(Executive Officer, Director)
BoardGeoff Pardo(Director)inPrattipati Laxminarain(Director)
Co-investorsAccelmed PartnersFemHealth VenturesBlueStone Venture PartnersEvidity Health CapitalGilde HealthcareMedical Technology Venture Partners+2 more
Prover Medical develops the ProVee System, a retrievable nitinol stent and delivery device that opens the obstructed prostatic urethra to relieve lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH) without cutting, heating, or removing prostate tissue.
HardwareHealthtechMedical Devices
Dr Conor Harkin(Founder)inRíona Ní Ghriallais(Founder)in
Co-investorsLightstone VenturesOrbiMedIreland Strategic Investment Fund
HealthtechIrvine, US
Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)
Co-investorsBlackRockEndeavour VisionRTW Investments L.P.Soleus CapitalvenBio Global StrategicVivo Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.